Skip to main content

Table 1 Mean age, gender, race, and myasthenia drug distribution in the two groups

From: Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study

  COVID Patients with myasthenia (n = 27) Non-COVID Patients with myasthenia (n = 64)
Mean age (±SD) 64.33 ± 18.42 (n = 27) 63.23 ± 18.60 (n = 64)
Mean age (±SD) for patients with exacerbation 51.5 ± 14.93 (n = 4) 64.13 ± 17.95 (n = 23)
Female 13 48.15% 36 56.25%
Male 13 48.15% 27 42.19%
Unknown 1 3.70% 1 1.56%
Caucasian 16 59.26% 46 71.88%
African American 4 14.81% 8 12.50%
Another racial group 7 25.93% 10 15.62%
Immune globulin intravenous 7 25.93% 13 20.31%
Methylprednisolone 9 33.33% 21 32.81%
Prednisone 18 66.67% 37 57.81%
Mycophenolate Mofetil 6 22.22% 3 4.69%
Pyridostigmine 16 59.26% 33 51.56%